Gold Price Weekly Forecast: XAU/USD bracing for another dose of covid vaccine news

  • Optimism about a covid vaccine shot down gold prices.
  • Additional headlines from the medical front, speculation about the Fed, and US retail sales are eyed.
  • Mid-November's daily chart is painting a bearish picture. 
  • The FX Poll is pointing to short term falls but long term gains.

Blinded by the light at the end of the tunnel – gold tumbled in response to a breakthrough in developing a vaccine for coronavirus. The implication is less fiscal and monetary stimulus, yet rising cases in the northern hemisphere may change the picture. 

This week in XAU/USD: Shot down by the vaccine, political uncertainty

Pfizer and BioNTech reported a 90% efficacy rate in their COVID-19 vaccine candidate. While the results are preliminary, the outcome seems promising not only for these firms – but also for three other efforts using the mRNA approach. 

Gold has been rising on hopes for additional fiscal stimulus, yet with prospects of returning back to normal, the urge for additional funds is weaker. XAU/USD tumbled down in response, dipping below $1,850.

On the other hand, the pandemic continues hitting the northern hemisphere, from rising cases in Japan, through increased European deaths and record hospitalizations in the US. Jerome Powell, Chairman of the Federal Reserve, reiterated the need for more support from both central banks and governments. 

What about the fiscal stimulus? Democratic candidate Joe Biden won the elections, but his party is unlikely to have a majority in the Senate, needed to pass ambitious support to the economy. Control of the upper chamber hinges on two runoff races in Georgia, due only in early January. 

While President Donald Trump has not conceded, he has ordered the White House to step back from talks about a new relief package, leaving the task to Republican lawmakers, who seem reluctant to strike an accord with Democrats. The stalemate in Washington has also put a lid on gold prices.

Next week in Gold: Pharma in focus

Who will be the next pharmaceutical firm to publish results from its Phase 3 trial? Massachusetts-based Moderna seems to be the front-runner. If its efficacy levels are similar to those of Pfizer/BioNTech, the yellow metal is set for another hit. The firm hinted that the fast spread of coronavirus in the US exposed more of its trial participants to the disease. 

XAU/USD traders would be wise to continue following covid statistics, especially in the US. If cases, hospitalizations, and deaths continue their upward trajectory, state governors could impose new restrictions. In turn, that would push lawmakers to get a fiscal relief package out the door – perhaps boosting gold's price. 

Overall, the virus is left, right and center, with a rising potential for stimulus serving as a bullish factor and vaccine news boosting the bears. Apart from Moderna, other firms to watch are AstraZeneca and Johnson & Johnson. 

The US presidential elections are winding down, with certifications from additional states due out during the week. Republicans are gradually coalescing around President-elect Biden. However, the races in Georgia are gaining traction. If Dems come ahead in opinion polls, it could support the precious metal. However, the margins are likely to be razor-thin, given the minuscule gaps in the first round for the Senate and the presidential race in Georgia – the former Vice-President is ahead by only 0.28%.

Retail sales stand out on the economic calendar. Expenditure figures from China kick off the week. An ongoing recovery in the world's second-largest economy implies higher demand for gold. Consumption figures in the US are critical for the economy. Yet, if the comeback remains robust, it would weaken the case for an injection of federal funds, potentially weighing on the metal. 

Here are the key events for gold on the economic calendar: 

XAU/USD technical analysis

Gold has dropped below the 50-day and 100-day Simple Moving Averages and still suffers from some downside momentum – bearish signs. On the other hand, XAU/USD is trading above the all-important 200-day SMA. 

Support awaits at $1,860, which was a cushion in late October. The next level to watch is $1,850, now a double bottom after halting the decline in November and September. Further below, $1,820 and $1,790 are noteworthy. 

Resistance is at $1,905, which is where the 50-day and 100-day SMAs converge. The next cap awaits at $1,935, which held gold prices down twice in recent weeks. The next barrier is at $1,965, which is November's high point. Next up, $1,995 and $2,020 are worth watching. 

Gold sentiment 

While rising virus cases could provide room for recovery, excitement about additional vaccine candidates may deal further blows to gold. 

The FX Poll is pointing to further pressure in the short term, followed by stabilization in the medium term and then a rally in the long term. Experts seem to have adjusted to the recent fall – all three targets have dropped in the past week.

Related Reads


Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.

Analysis feed

FXStreet Trading Signals now available!

Access to real-time signals, community and guidance now!

Latest Analysis

Latest Forex Analysis

Editors’ Picks

AUD/USD: Upbeat China PMIs favor bulls near fresh three month high around 0.7400

AUD/USD remains positive after China’s activity data for November flashed welcome signs. November’s China NBS Manufacturing PMI, Aussie TD Securities Inflation flashed more than expected results. Market mood stays cautious optimistic amid vaccine hopes, Brexit jitters and Aussie-China tussle.


EUR/USD: Refreshes three-month high towards 1.2000, battles triangle resistance

EUR/USD eases from fresh high since September 01. The pair rose to the highest in three months before a few hours but couldn’t cross the upper line of a five-week-old ascending triangle formation. RSI conditions warrant caution, bears are less likely to take entries above 1.1870.


NZD/USD refreshes 2.5-year high on strong China PMI above 0.7400

NZD/USD rises to the fresh high since June 2018 after China data. China’s NBS Manufacturing PMI, Non-Manufacturing PMI beat market forecasts in November. ANZ Business Confidence, Activity Outlook also came in positive for November.


Gold: Trades below 200-day MA for first since March

Gold is trading below the widely-followed 200-day Simple Moving Average (SMA) for the first time since March. The metal is changing hands near $1,783 per ounce, representing a 0.25% loss on the day. 

Gold news

Black Friday 2020 Discounts!

Learn to trade with the best! Don't miss the most experienced traders and speakers in FXStreet Premium webinars. Also if you are a Premium member you can get real-time FXS Signals and receive daily market analysis with the best forex insights!

More info

Forex Majors